USE OF LONG-ACTING SOMATOSTATIN ANALOG, LANREOTIDE, IN NEUROENDOCRINE TUMORS

1994 ◽  
Author(s):  
L CANOBBIO ◽  
D CANNATA ◽  
L MIGLIETTA ◽  
M PACE ◽  
F BOCCARDO
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Analog ◽  
Long Acting

Hepatic cytoreduction followed by a novel long-acting somatostatin analog: A paradigm for intractable neuroendocrine tumors metastatic to the liver

Surgery ◽  
2001 ◽  
Vol 130 (6) ◽  
pp. 954-962 ◽  
Author(s):  
Mathew H. Chung ◽  
Joseph Pisegna ◽  
Mitchell Spirt ◽  
Armando E. Giuliano ◽  
Wei Ye ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Analog ◽  
Long Acting

Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms

1999 ◽  
Vol 17 (4) ◽  
pp. 1111-1111 ◽  
Author(s):  
A.N.M. Wymenga ◽  
B. Eriksson ◽  
P.I. Salmela ◽  
M.B. Jacobsen ◽  
E.J.D.G. Van Cutsem ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Neuroendocrine Tumors ◽  
Tumor Size ◽  
Acid Output ◽  
Symptomatic Improvement ◽  
Carcinoid Tumors ◽  
Somatostatin Analog ◽  
Prolonged Release ◽  
Antitumor Effects ◽  
Long Acting

PURPOSE: To evaluate the prolonged release (PR) of the long-acting somatostatin analog lanreotide in patients with gastrointestinal neuroendocrine tumors and its effect on hormone-related symptomatology, tumor markers, tumor size, tolerability, and quality of life (QOL). PATIENTS AND METHODS: Eligible patients had the following substantial daily symptoms: for patients with carcinoid tumors, three or more stools and/or 1.5 or more flushing episodes; for patients with gastrinoma, greater than 50% elevated basic acid output; and for patients with vasoactive intestinal peptide-secreting tumors (VIPomas), four or more stools and/or a stool volume of ≥ 800 mL, a measurable tumor, and an elevated biochemical tumor marker (≥ two times the upper limit of the normal reference range). Lanreotide PR was administered intramuscularly every 14 days at 30 mg for 6 months. We measured efficacy by studying symptoms, tumor markers, tumor size, and QOL. Side effects were scored according to the National Cancer Institute's toxicity grading system and ultrasound examination of the gallbladder. RESULTS: Fifty-five patients were included in the study (48 patients with carcinoid tumors, six patients with gastrinoma, and one patient with VIPoma). Symptomatic improvement (> 50% reduction) occurred in 38% of the assessable patients with carcinoid tumors, in 67% of the gastrinoma patients, and in the VIPoma patient. Tumor markers normalized in two of 45 assessable patients, 19 patients exhibited a reduction (> 50%), 19 patients exhibited no change, and tumor markers rose by more than 50% in five patients. Tumor size was reduced in two of 31 assessable patients and remained stable in 25 patients; four patients experienced progression. QOL assessments after 1 month showed improvements in emotional and cognitive function, and diminished fatigue, sleeping disorders, and diarrhea. Eight of 30 assessable patients developed gallstones. CONCLUSION: Lanreotide PR is a well-tolerated somatostatin analog with significant clinical, biochemical, and antitumor effects that bring about a significant improvement in QOL for patients with neuroendocrine tumors.

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

2000 ◽  
Vol 95 (11) ◽  
pp. 3276-3281 ◽  
Author(s):  
Michel Ducreux ◽  
Philippe Ruszniewski ◽  
Jean-Alain Chayvialle ◽  
Joelle Blumberg ◽  
Denis Cloarec ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Analog ◽  
Antitumoral Effect ◽  
Long Acting

Octreotide, a long-acting somatostatin analog, in the management of postoperative dumping syndrome

1993 ◽  
Vol 38 (2) ◽  
pp. 359-364 ◽  
Author(s):  
Cornelis B. H. W. Lamers ◽  
Anne M. Bijlstra ◽  
Alan G. Harris
Keyword(s):  
Somatostatin Analog ◽  
Dumping Syndrome ◽  
Long Acting

Treatment of Severe Cryptosporidium-Related Diarrhea with Octreotide in a Patient with AIDS

1988 ◽  
Vol 22 (2) ◽  
pp. 134-136 ◽  
Author(s):  
Michael D. Katz ◽  
Brian L. Erstad ◽  
Cathryn Rose
Keyword(s):  
Gastrointestinal Hormones ◽  
Somatostatin Analog ◽  
Secretory Diarrhea ◽  
Inhibitory Effects ◽  
Severe Diarrhea ◽  
Immunosuppressed Patients ◽  
Acquired Immunodeficiency ◽  
Antiparasitic Drugs ◽  
Long Acting ◽  
Immunodeficiency Syndrome

Cryptosporidiosis commonly causes severe diarrhea in immunosuppressed patients. There currently are no antiparasitic drugs consistently effective for this infection. This case describes a 26-year-old hemophiliac patient with acquired immunodeficiency syndrome and cryptosporidiosis whose diarrhea improved with continuous intravenous administration of a long-acting somatostatin analog, octreotide. Somatostatin has a variety of inhibitory effects on gastrointestinal hormones as well as a possible nonspecific effect on gastrointestinal mucosal fluid and electrolyte secretion. The somatostatin analog should be considered for patients with secretory diarrhea refractory to other forms of therapy.

Sign in / Sign up

Export Citation Format

Share Document